(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Sponsor: Blueprint Medicines Corporation
This PHASE1 trial investigates Aggressive Systemic Mastocytosis and Mast Cell Leukemia and is currently completed. Blueprint Medicines Corporation leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Apr 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — Jun 2020 [monthly]
Recruiting PHASE1
-
Jun 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Aug 2018 — Jun 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Blueprint Medicines Corporation
For direct contact, visit the study record on ClinicalTrials.gov .